Global Menstrual Cramps Treatment Market, By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Diagnosis (Ultrasound, Laparoscopy, CT scan, magnetic resonance imaging (MRI), Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Menstrual Cramps Treatment Market Analysis and Size
Menstrual cramps are strong cramps that start in the lower abdomen and can spread to the back and lower legs. Most women begin to experience intense pain in their early adolescence, roughly five years after the menstrual cycle begins. In medical words, this is known as Dysmenorrhea. According to a study published in March 2021 titled "The Impact of the COVID-19 Pandemic on Women's Reproductive Health," 46 percent of women reported a change in their menstrual cycle since the pandemic began, with 30 percent of new dysmenorrhea cases. COVID-19 has thus had a considerable impact on the menstrual cramps treatment market.
Data Bridge Market Research analyses that the global menstrual cramps treatment market which was USD 4,338.302 million in 2022, is expected to reach USD 9,145.12 million by 2030, and is expected to undergo a CAGR of 8.30% during the forecast period of 2023 to 2030. “Primary Dysmenorrhea” dominates the type segment of the global menstrual cramps treatment market due to high prevalence of menstrual cramps treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Menstrual Cramps Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Diagnosis (Ultrasound, Laparoscopy, CT scan, magnetic resonance imaging (MRI), Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), AbbVie Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada)
|
|
Market Opportunities
|
|
Market Definition
Dysmenorrhea is a medical name for menstrual cramps in which a woman experiences severe cramps in her lower abdomen that can migrate to her lower legs and back. Dysmenorrhea affects the majority of women during puberty, usually within four to five years following their first menstrual cycle. During menstruation, substances called prostaglandins are released into the uterine lining. These prostaglandins generate uterine muscle contractions, which are uncomfortable and reduce blood and oxygen flow to the uterus. Menstrual cramps can often be relieved with over-the-counter pain medications. Ibuprofen and other nonsteroidal anti-inflammatory medications (NSAIDs) can help ease pain.
Global Menstrual Cramps Treatment Market Dynamics
Drivers
- High Prevalence of Dysmenorrhea
Dysmenorrhea is a widespread condition, affecting a substantial portion of individuals with menstrual cycles. The sheer prevalence of dysmenorrhea acts as a powerful driver for the market, spurring the demand for effective treatment options, including pharmaceuticals and therapies.
- Increasing Awareness and Education
The growing awareness of dysmenorrhea and its impact on daily life has resulted in increased education and advocacy efforts. Healthcare professionals and advocacy groups have played a vital role in raising awareness and ensuring that individuals are aware of the available treatment options.
- Advancements in Menstrual Cramps Treatment
Continuous research and development initiatives have led to significant advancements in menstrual cramps treatment. New pharmaceutical formulations, cutting-edge pain relief technologies, and alternative remedies have enriched the arsenal of treatment options, promising improved symptom management.
Opportunities
- Personalized Treatment Plans
Tailoring treatment plans to individual needs and preferences offers a promising opportunity for improved symptom management. Healthcare providers can collaborate with patients to develop personalized approaches that may encompass a combination of treatments.
- Digital Health and Telemedicine
The ascendancy of digital health and telemedicine platforms provides convenient access to healthcare providers and information about menstrual cramps treatment. Telehealth consultations allow individuals to discuss their symptoms and receive guidance from the comfort of their homes.
Restraints/Challenges
- Side Effects of Pharmaceuticals
While pharmaceuticals provide effective pain relief for many individuals, some may experience side effects or contraindications. Issues such as nausea, gastrointestinal discomfort, and contraindications for specific medications can limit treatment options.
-
Regulatory Compliance and Safety
The development and approval of therapies for rare diseases such as menstrual cramps treatment involve navigating regulatory hurdles. Obtaining orphan drug designation and meeting regulatory requirements can be time-consuming and costly.
This global menstrual cramps treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global menstrual cramps treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2021, Nua had announced the launch of Cramp Comfort, a first-of-its-kind product to help with period pain. Nua, a women's wellness company, has introduced a novel self-heating patch that may provide up to 8 hours of heat to relieve period pain. Cramp Comfort is comprised entirely of natural substances and was developed after extensive study and a thorough understanding of consumer demands. A pack of three heat patches costs INR 299
Global Menstrual Cramps Treatment Market Scope
The global menstrual cramps treatment market is segmented on the basis of type, treatment type, diagnosis, mode of prescription, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
Treatment Type
- Medication
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Combined Oral Contraceptives
- Others
- Therapy
- Surgery
- Others
Diagnosis
- Ultrasound
- Laparoscopy
- CT Scan
- Magnetic Resonance Imaging (MRI)
- Others
Mode of Prescription
- Over the Counter
- Prescription
Route of Administration
- Oral
- Parenteral
- Implants
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Menstrual Cramps Treatment Market Regional Analysis/Insights
The global menstrual cramps treatment market is analysed and market size insights and trends are provided by type, treatment type, diagnosis, mode of prescription, route of administration, end-user and distribution channel as referenced above.
The countries covered in the global menstrual cramps treatment market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global menstrual cramps treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2023 to 2030, due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global menstrual cramps treatment market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global menstrual cramps treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global menstrual cramps treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global menstrual cramps treatment market. The data is available for historic period 2015 to 2020.
Competitive Landscape and Global Menstrual Cramps Treatment Market Share Analysis
The global menstrual cramps treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to global menstrual cramps treatment market.
Some of the major players operating in the global menstrual cramps treatment market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Baxter (U.S.)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Allergan (Ireland)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)
SKU-